3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Recurrence
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hematologic Diseases
1
Blood Protein Disorders
1
Interventions
fludarabine
3
filanesib
2
Tacrolimus
2
Steroids
2
Injections, Subcutaneous
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Dexamethasone
2
Bortezomib
2
Alemtuzumab
2
ofatumumab
1
fludarabine phosphate
1
Zoledronic Acid
1
Whole-Body Irradiation
1
Stem Cell Transplantation
1
Proteasome Inhibitors
1
Mycophenolic Acid
1
Lenalidomide
1
KW-2478
1
Hsp90 inhibitor KU757
1
Denosumab
1
Cyclophosphamide
1
Clonal Hematopoiesis
1
Chromatin Immunoprecipitation Sequencing
1
CLR1404
1
Busulfan
1
Blood Cell Count
1
ARQ531
1
ARQ 197
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paraproteinemias
×
CLR1404
×
Other hematologic neoplasm
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled